335. Safety and tolerability results from a phase 2b, double-blind trial with an open-label extension of GH001 in treatment-resistant depression
International Journal of Neuropsychopharmacology September 1, 2026 B. T. Baune, T. Benway, D. Gregory et al.
Abstract Background Treatment-resistant depression (TRD) is a chronic condition affecting approximately 30% of patients with major depressive disorder, posing a significant unmet need for safe and effective treatments. GH001, an inhaled formulation of mebufotenin (5-MeO-DMT), has shown good tolerability and safety in early stage clinical trials in healthy volunteers and patients with TRD. Aims...